New research links atopic dermatitis to a specific immune signaling pathway. Scientists have identified sphingosine 1-phosphate (S1P) as a key driver of inflammation in the chronic skin condition.
Patients with atopic dermatitis show elevated circulating S1P levels. The study found S1P receptor 1 (S1PR1) boosts production of inflammatory cytokines IL-13 and IL-9, while S1PR5 suppresses them. This receptor imbalance appears central to persistent inflammation.
Researchers indicate targeting this pathway could yield new treatments. However, findings derive from laboratory experiments and require clinical validation.